Inhye E Ahn

14PUBLICATIONS
81CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Central and Eastern European languages (incl. Russian)Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jun 23, 2026
SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLL.

|Dec 17, 2025
A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study.

Andy Itsara, Victoria M Rogness, Laura Samples

|Oct 24, 2025
Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL.

Thomas Chatzikonstantinou, Mariia Mikhaleva, Christian Brieghel

|Dec 07, 2024
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.

Matthew S Davids, Christine E Ryan, Benjamin L Lampson

|Jan 01, 2024
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.

Inhye E Ahn, Danielle M Brander, Yue Ren

|Jun 14, 2023
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.

Jennifer A Woyach, Paolo Ghia, John C Byrd

Pageof 3

Frequent Collaborators

5 joint publications

Clare Sun

4 joint publications

Erika M Gaglione

3 joint publications

Jennifer R Brown

3 joint publications

Xin Tian